The second article in this series, Standards for Clinical Trials in Male and Female Sexual Dysfunction, focuses on measurement of patient-reported outcomes (PROs). Together with the design of appropriate phase I to phase IV clinical trials, the development, validation, choice, and implementation of valid PRO measurements-the focus of the present article-form the foundation of research on treatments for male and female sexual dysfunctions. PRO measurements are assessments of any aspect of a patient's health status that come directly from the patient (ie, without the interpretation of the patient's responses by a physician or anyone else). PROs are essential for assessing male and female sexual dysfunction and treatment response, including sy...
Introduction. A limiting step in the evaluation of female sexual dysfunction (FSD) is the availabili...
Introduction: Sexual pleasure is a central aspect of human sexuality; however, no validated measurem...
Introduction. There are limited outcome data on the etiology and efficacy of psychological intervent...
The second article in this series, Standards for Clinical Trials in Male and Female Sexual Dysfuncti...
This series of articles outlines standards for clinical trials of treatments for male and female sex...
This series of articles, Standards for Clinical Trials in Male and Female Sexual Dysfunction, began ...
The focus of this article, the fourth in the series, Standards for Clinical Trials in Male and Femal...
Defining and measuring Female Sexual Dysfunction (FSD) is a complex and challenging task. Several fa...
Abstract Background For the treatment of female sexual dysfunction, the most relevant outcome measur...
Introduction. A considerable number of double-blind randomized controlled studies investigating the ...
Background: Efficacy of on-demand drugs for women with hypoactive sexual desire disorder or female s...
Background: Efficacy of on-demand drugs for women with hypoactive sexual desire disorder or female s...
Background\ud With data from a diverse sample of patients either in treatment for cancer or post-tre...
Background: Practitioners and researchers require an outcome measure that accurately identifies the ...
Introduction. A limiting step in the evaluation of female sexual dysfunction (FSD) is the availabili...
Introduction: Sexual pleasure is a central aspect of human sexuality; however, no validated measurem...
Introduction. There are limited outcome data on the etiology and efficacy of psychological intervent...
The second article in this series, Standards for Clinical Trials in Male and Female Sexual Dysfuncti...
This series of articles outlines standards for clinical trials of treatments for male and female sex...
This series of articles, Standards for Clinical Trials in Male and Female Sexual Dysfunction, began ...
The focus of this article, the fourth in the series, Standards for Clinical Trials in Male and Femal...
Defining and measuring Female Sexual Dysfunction (FSD) is a complex and challenging task. Several fa...
Abstract Background For the treatment of female sexual dysfunction, the most relevant outcome measur...
Introduction. A considerable number of double-blind randomized controlled studies investigating the ...
Background: Efficacy of on-demand drugs for women with hypoactive sexual desire disorder or female s...
Background: Efficacy of on-demand drugs for women with hypoactive sexual desire disorder or female s...
Background\ud With data from a diverse sample of patients either in treatment for cancer or post-tre...
Background: Practitioners and researchers require an outcome measure that accurately identifies the ...
Introduction. A limiting step in the evaluation of female sexual dysfunction (FSD) is the availabili...
Introduction: Sexual pleasure is a central aspect of human sexuality; however, no validated measurem...
Introduction. There are limited outcome data on the etiology and efficacy of psychological intervent...